Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastroesophageal Reflux Disease (GERD): full-pipeline trial registry
3 of 6 indexed Gastroesophageal Reflux Disease (GERD) trials are currently recruiting.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Gastroesophageal Reflux Disease (GERD): 6 US clinical trials tracked, 3 recruiting.
Gastroesophageal Reflux Disease (GERD) is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of North Carolina, Chapel Hill, running 2 of these trials.
Enrollment posture brief
Registry condition gastroesophageal-reflux-disease-gerd
OPEN 3 | RECR 50% | LATE 1 | EARLY 1 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Gastroesophageal Reflux Disease (GERD) lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastroesophageal Reflux Disease (GERD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastroesophageal Reflux Disease (GERD) is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Gastroesophageal Reflux Disease (GERD) research.
University of North Carolina, Chapel Hill accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastroesophageal Reflux Disease (GERD) enrolment sits around 255 participants.
Median target enrolment is 255 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.
-
Gastroesophageal Reflux Disease (GERD) research leans observational.
2 interventional and 4 observational studies make up this index (33.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Esophageal Cancer Risk Registry
University of Pittsburgh
NCT00260585
Indiana University Gastrointestinal Motility Diagnosis Registry
Indiana University
NCT04506593
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Takeda
NCT02616302
Racial Disparity in Barrett's Esophagus
University of North Carolina, Chapel Hill
NCT01374074
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Eisai
NCT00839306
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
University of North Carolina, Chapel Hill
NCT01373125
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastroesophageal Reflux Disease (GERD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastroesophageal Reflux Disease (GERD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastroesophageal Reflux Disease (GERD) page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Gastroesophageal Reflux Disease (GERD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of North Carolina, Chapel Hill sponsors the most Gastroesophageal Reflux Disease (GERD) trials on record, review their full trial history before evaluating a specific study. See University of North Carolina, Chapel Hill's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastroesophageal Reflux Disease (GERD) condition card totals 6 registered trials; most-linked intervention Ranitidine; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.